SEC Tracker
Get the app
NPCE · XBRL financial data

NeuroPace financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (NPCE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers16,42718,012*18,12419,25621,06021,466*22,52423,52027,35426,588*22,06822,826
Cost of goods and services sold4,1944,467*4,7815,1225,6405,278*5,1825,3886,1866,010*4,0203,920
Gross profit12,23313,545*13,34314,13415,42016,188*17,34218,13221,16820,578*18,04818,906
Research and development4,7955,377*5,7846,0655,7546,050*7,4406,8456,5767,027*7,1896,898
Selling, general and administrative13,38813,219*15,10414,29913,90913,791*15,049—————
General and administrative———4,5433,9803,840*4,0466,0684,5944,382*4,8445,027
Total operating expenses18,18318,596*20,88820,36419,66319,841*22,48924,95623,76822,345*23,61624,049
Operating income (loss)(5,950)(5,051)*(7,545)(6,230)(4,243)(3,653)*(5,147)(6,824)(2,600)(1,767)*(5,568)(5,143)
Interest income769822*827762754681*793718667638*565523
Interest expense2,1912,236*2,2582,1662,1822,192*2,1532,0591,6451,600*1,5211,539
Other income (expense)115265*51120219(86)*(82)(486)820*(165)(41)
Income tax expense (benefit)0—000—0000*0—
Net income (loss)(7,257)(6,200)*(8,925)(7,514)(5,452)(5,250)*(6,589)(8,651)(3,496)(2,729)*(6,689)(6,200)
Earnings per share, basic USD per share(0.28)(0.23)*(0.32)(0.26)(0.19)(0.18)*(0.21)(0.26)(0.11)(0.08)*(0.20)(0.18)
Earnings per share, diluted USD per share(0.28)(0.23)*(0.32)(0.26)(0.19)(0.18)*(0.21)(0.26)(0.11)(0.08)*(0.20)(0.18)
Weighted average shares, basic thousands of shares26,01726,800*28,28528,85329,44529,910*31,48132,86333,13533,386*33,71734,104
Weighted average shares, diluted thousands of shares26,01726,800*28,28528,85329,44529,910*31,48132,86333,13533,386*33,71734,104

Balance sheet

CSV

Fiscal quarters (NPCE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents9,71718,05812,99812,84415,41813,43027,01922,85720,64821,69214,77912,538
Short-term investments51,63148,39645,94742,69341,41239,32539,24339,28439,36639,36639,20239,161
Accounts receivable11,27912,31411,63111,24211,56112,85115,43513,55414,93814,68114,78814,930
Inventory9,75911,21411,41611,36312,08413,38113,58016,34618,13516,89616,69418,111
Prepaid and other current assets1,5882,7372,2622,0842,1162,3522,2011,7012,2431,4381,5151,453
Total current assets83,97492,71984,25480,22682,59181,33997,47893,74295,33094,07386,97886,193
Property and equipment, net9491,0031,0489981,0411,0521,1601,1561,1081,1251,2831,243
Right-of-use asset13,77413,40513,02712,64112,24611,84311,43011,00710,57510,1329,6799,216
Total assets99,300107,65198,85394,38996,30394,647110,205106,114107,255105,56598,89896,991
Accounts payable1,2072,3323,2682,2902,1602,9544,0464,7214,5902,2174,5124,204
Accrued liabilities10,03611,1807,2907,74510,0729,7878,0589,74012,31713,3399,34410,850
Total current liabilities12,81516,22913,11012,58514,78115,15614,70717,14319,60717,81416,16817,433
Long-term debt55,88956,95458,03959,01659,26659,52559,78858,61658,74858,88459,02159,014
Lease liability, non-current14,23313,81413,36312,90312,43311,95311,44110,91710,3829,8369,2558,661
Total liabilities82,93786,99784,51284,50486,48086,63485,93686,67688,73786,53484,44485,108
Accumulated deficit(497,609)(503,809)(512,734)(520,248)(525,700)(530,950)(537,539)(546,190)(549,686)(552,415)(559,104)(565,304)
Total stockholders' equity16,36320,65414,3419,8859,8238,01324,26919,43818,51819,03114,45411,883
Total liabilities and equity99,300107,65198,85394,38996,30394,647110,205106,114107,255105,56598,89896,991
Common shares outstanding (cover page) thousands of shares26,28428,34528,76829,19729,84832,56032,79933,08133,30833,66734,09434,324

Cash flows

CSV

Fiscal quarters (NPCE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(7,257)(6,200)*(8,925)(7,514)(5,452)(5,250)*(6,589)(8,651)(3,496)(2,729)*(6,689)(6,200)
Stock-based compensation2,421*2,357*2,5402,548*2,591*2,603*2,6263,228*2,628*2,607*2,2782,303*
Net cash from operating activities(2,302)*(3,341)*(7,528)(3,900)*(1,724)*(4,797)*(7,482)(2,086)*(1,944)*506*(5,900)(3,903)*
Purchases of property and equipment9*32*10463*100*39*37168*30*97*117125*
Net cash from investing activities4,191*3,468*2,3963,237*1,400*1,961*(37)(168)*(30)*(97)*(117)(125)*
Share repurchases——00*0*0*49,5460*0*0*00*
Net cash from financing activities(27)*8,214*72509*2,898*848*21,108(1,908)*(235)*635*(166)1,176*
Net change in cash1,862*8,341*(5,060)(154)*2,574*(1,988)*13,589(4,162)*(2,209)*1,044*(6,183)(2,852)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
NeuroPace12,53822,826(3,903)*34.3M13.2 quarters 10-QJun 30, 2026
ClearPoint Neuro46,18412,075(20,100)32.1M6.6 quarters 10-QSep 30, 2026
Outset Medical35,00531,635(9,635)*18.8M15.3 quarters 10-QJun 30, 2026
SS Innovations International13,647not reported(4,235)*200.4M3.2 quarters 10-QJun 30, 2026
EBR Systems59,3502,637(17,194)*75.3M5.0 quarters 10-QJun 30, 2026
Treace Medical Concepts12,61045,376(4,698)*65.0M9.7 quarters 10-QJun 30, 2026
Bioventus30,709142,44220,658*not reported— 10-QSep 26, 2026
Orthopediatrics17,14172,6614,506*26.1M— 10-QSep 30, 2026
Carlsmed46,244not reported(7,358)*27.3M9.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.